Top Stories
Financing will support training of foundation models and expansion of the Lab-in-the-Loop engine.
The 600,000–square-foot facility will create close to 500 new skilled jobs.
The radiopharma developer said it plans to resubmit an NDA after the US regulator raised chemistry, manufacturing and controls (CMC) and facility concerns.
ABCL635, a long-acting NK-3R antagonist, achieved statistically significant reductions in both the frequency and severity of vasomotor symptoms.
The company said its IL-17A/F nanobody sonelokimab hit week-16 endpoints in biologic-naïve patients of the IZAR-1 study in psoriatic arthritis (PsA).
Conference News
Investor and physician feedback suggests that divesiran's potential for quarterly dosing could indeed give it a leg up over Takeda's once-weekly rival in polycythemia vera should its efficacy hold up in Phase III.
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2026."Our second quarter results reflect a str...
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A$120.7 million in cash, cash equivalents, a...
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R AgonistSEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027Cash Pos...
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readinessContinued progress toward s...
